rs2200733 — PITX2 PITX2 4q25 AF susceptibility variant

PITX2 4q25 — The Master Switch for the Left Atrium's Electrical Identity

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting over 37 million people worldwide and carrying a fivefold increased risk of ischaemic stroke. The variant rs2200733 at chromosome 4q25 is the strongest single GWAS signal ever found for AF susceptibility — discovered in the landmark 2007 Nature paper by Gudbjartsson et al. and since replicated across dozens of populations and hundreds of thousands of participants. The variant sits in a non-coding intergenic region near PITX2 (paired-like homeodomain transcription factor 2)¹¹ PITX2 (paired-like homeodomain transcription factor 2)
a transcription factor essential for left-right body asymmetry and left atrial identity during cardiac development, and its effect is not to alter the PITX2 protein but to reduce how much PITX2 the left atrium produces.

The Mechanism

PITX2 is selectively expressed in the adult left atrium²² left atrium
the upper left chamber of the heart, the primary driver of AF when ectopic electrical impulses originate from pulmonary vein sleeves or the posterior left atrial wall and is largely absent from the right atrium and ventricles. Its role is to maintain the left atrium's distinct "working myocardium" identity by suppressing the sinoatrial node (SAN) pacemaker program³³ sinoatrial node (SAN) pacemaker program
the SAN is the heart's natural pacemaker, located in the right atrium; its gene expression profile — rapid automaticity, slow conduction — is appropriate there but catastrophic if it activates in left atrial tissue.

Wang et al. 2010 (PNAS)⁴⁴ Wang et al. 2010 (PNAS)
Pitx2 prevents susceptibility to atrial arrhythmias by inhibiting left-sided pacemaker specification. Proc Natl Acad Sci USA. 2010;107(21):9753–9758. demonstrated that PITX2 directly binds and represses Shox2 — a master activator of the SAN gene program — along with downstream pacemaker genes HCN4 (funny current channel), Kcnq1 (potassium channel), and Tbx3 (transcription factor). When PITX2 levels fall by even 50% (haploinsufficiency), mice develop atrial flutter and tachycardia upon electrical stimulation, and SAN-specific gene expression inappropriately reactivates in left atrial tissue.

The rs2200733 T allele acts as a regulatory variant that reduces PITX2 expression in the left atrium. The consequence — less PITX2 → less SAN suppression → ectopic automaticity and triggered activity in the pulmonary vein sleeves and posterior left atrial wall → AF. Beyond pacemaker de-suppression, Syeda et al. 2017⁵⁵ Syeda et al. 2017
PITX2-dependent gene regulation in atrial fibrillation and rhythm control. J Physiol. 2017;595(12):4019–4026. established that PITX2 deficiency also drives electrical remodelling (shortened atrial action potential, reduced gap junction coupling) and structural remodelling (fibrosis), both of which sustain AF once initiated. More recently, PITX2 deficiency has been shown to cause atrial mitochondrial dysfunction and a metabolic shift toward glycolysis that may underlie the structural changes.

The Evidence

The original discovery came from Gudbjartsson et al. in a 2007 genome-wide association study⁶⁶ a 2007 genome-wide association study
Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature. 2007;448(7151):353–357. spanning European and Chinese cohorts. Two variants at 4q25 were identified; rs2200733 was the stronger signal, conferring a 1.72-fold increased risk per copy in Europeans and a 1.42-fold risk per copy in Chinese populations. Approximately 35% of Europeans carry at least one T allele; in East Asian populations the T allele reaches ~49% frequency, making rs2200733 one of the most ethnically variable major AF risk variants.

A 2014 meta-analysis by Ferrán et al.⁷⁷ Ferrán et al.
Association between rs2200733 and rs7193343 genetic variants and atrial fibrillation in a Spanish population, and meta-analysis of previous studies. Rev Esp Cardiol. 2014;68(5):381–388. pooled data across multiple populations and confirmed an overall OR of 1.71 (95% CI 1.54–1.90) for rs2200733 and AF. This places rs2200733 among the highest-effect common variants in cardiovascular disease genetics — comparable in magnitude to APOE4 for Alzheimer's disease risk.

Population-specific replication in a Greek cohort of 295 individuals Kalinderi et al. 2015⁸⁸ Kalinderi et al. 2015
Hellenic J Cardiol. 2015;56(3):229–235. found the TT genotype in 13.2% of AF patients versus only 2.3% of controls. In Chinese Han subjects Han et al. 2023⁹⁹ Han et al. 2023
Anatol J Cardiol. 2023;27(3):160–166., the TT genotype conferred OR 5.08 (95% CI 1.65–15.6), consistent with East Asian populations' higher T allele frequency and correspondingly higher TT homozygote prevalence.

Beyond risk, rs2200733 predicts treatment response: a 2015 meta-analysis of 991 patients undergoing catheter ablation Shoemaker et al. 2015¹⁰¹⁰ Shoemaker et al. 2015
Circ Arrhythm Electrophysiol. 2015;8(2):296–302. found that rs2200733 T allele carriers had a 1.4-fold increased risk of AF recurrence after ablation (HR 1.3, 95% CI 1.1–1.6), making genotyping clinically relevant for procedure planning.

Practical Actions

For T allele carriers, the priorities are: knowing your genotype's implications for stroke risk so you can act if AF is ever diagnosed; heart rate monitoring to catch paroxysmal AF early; avoiding triggers known to increase AF risk in genetically susceptible individuals; and informing clinical decisions about rhythm vs rate control strategy and ablation prognosis if AF is diagnosed.

The rs2200733 variant does not directly cause AF — it increases susceptibility. Whether AF develops depends on modifying factors including cardiovascular fitness, blood pressure, thyroid function, sleep apnoea, alcohol intake, and body weight. These factors interact with the underlying PITX2 deficiency to determine whether arrhythmia manifests.

Interactions

The 4q25 locus contains multiple AF-associated variants in linkage disequilibrium. rs10033464 is the second significant variant identified by Gudbjartsson et al. (OR ~1.39 per copy in Europeans), located ~10 kb from rs2200733. These variants are partially correlated but represent related yet independent signals at the same PITX2 regulatory locus. Carrying risk alleles at both rs2200733 and rs10033464 compounds AF risk — this combination is a candidate for a compound action.

Several additional 4q25 variants (rs6817105, rs3853445) have been identified in GWAS follow-up studies and may tag additional PITX2 regulatory elements. No pharmacogenomic drug-gene interactions have been formally established, but the Shoemaker 2015 data support using rs2200733 status when counselling patients about ablation prognosis.